MPO and ganglioneuroma: AAVs have a strong safety profile and permit long-term transgene expression in postmitotic cells (in the liver), making them ideally suited to treat chronic and remitting diseases, such as MPO-ANCA GN, which typically requires ongoing treatment that may be prolonged over years (70–72).